Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc dose-ranging study in asymptomatic HIV
NCT00643643Phase 2Completed
- Sponsor
- ViiV Healthcare
- Start
- Oct 2002
- Primary completion
- Jun 2003
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of maraviroc in human immunodeficiency virus infection (HIV) (5 arms), sponsored by ViiV Healthcare. Primary endpoints: Change from baseline in viral load at Day 11, Pharmacokinetic profile of UK-427,857 at Day 10 and 1 more. Started Oct 2002; status: completed.
02
Drugs
maraviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00643643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00643643.